Selective inhibitor of Tank Binding Kinase 1 (TBK1) and IκB kinase ε (IKKε) — kinases activated in obesity that impair insulin signaling and increase energy expenditure suppression. By inhibiting these, amlexanox restores normal energy expenditure and insulin sensitivity in obese metabolic states.
Studies have administered: 25–100mg twice daily oral in metabolic research studies
Reilly et al. (2013) Nature Medicine: reduced body weight and adiposity in obese mice. Human phase 2 (Saltiel group): a subset of obese subjects with metabolic inflammation showed significant weight loss and improved insulin sensitivity. Biomarker-selected responder analysis key finding.
Diarrhea, nausea; elevated transaminases in some subjects; mouth ulcers at topical doses; well-characterized safety from aphthous ulcer indication
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on Amlexanox — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat